Детские инфекции (Москва) (Sep 2016)

OSELTAMIVIR AS ANTIVIRAL THERAPY OF INFLUENZA A(H1N1)pdm09 IN CHILDREN AND ADULTS

  • L. V. Osidak,
  • V. V. Zarubaev,
  • O. I. Afanasyeva,
  • L. V. Voloshuk,
  • V. V. Gonchar,
  • М. М. Pisareva,
  • E. G. Golovacheva,
  • E. А. Dondurey,
  • V. S. Afanasyeva,
  • V. F. Suhovetskaya,
  • E. V. Obraztsova,
  • E. G. Rozhkova,
  • А. Gо,
  • V. M. Guseva,
  • A. A. Shtro,
  • N. Y. Kaika

DOI
https://doi.org/10.22627/2072-8107-2016-15-3-19-25
Journal volume & issue
Vol. 15, no. 3
pp. 19 – 25

Abstract

Read online

In this article are presented the results of comparative of experimental (on cell cultures) study of the influenza virus strains sensitivity to neuraminidase inhibitor — Oseltamivir and blocker of M-canal — Rimantadin аnd the results of study effectiveness of the inclusion in the complex therapy of 331 hospitalized patients (children and adults) rapy of А(Н1N1)pdm09 antiviral drug — inhibitor of neuraminidase Oseltamivir that occurred during the epidemic seasons 2009—2010 and 2015—2016 in terms of observational clinical studies. It is shown that this drug, can be successfully used in the treatment of children and adults with influenza А(Н1N1)pdm09 during 8—9 years after beginning of pandemic cycle.

Keywords